Skip to content
DataLookout
Menu

NCT06816810

A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Sep 2027 Show 6 more changesShow less
    • Eligibility criteria expanded, about 3 words
    • Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Start date changed from estimate of Mar 2025 to Jun 9, 2025
    • Secondary endpoints: details revised at 7 of 7 entries
    • Site contact updated
    • Publications: details revised at 27 of 28 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Timeframe: Throughout enrollment (4 weeks of screening) to the end of treatment at 48 weeks and 4-week safety follow-up.
Efficacy of Hydroxychloroquine (HCQ) in Delaying Clinical Motor Progression Using MDS-UPDRS Part III
Timeframe: Throughout enrollment to the end of treatment at 48 weeks. MDS-UPDRS Part III will be evaluated at baseline, 24 weeks and 48 weeks.

Secondary (7)

Efficacy of Hydroxychloroquine (HCQ) in Delaying Clinical PD Progression Using CGI-C Scale
Efficacy of Hydroxychloroquine (HCQ) in Delaying Clinical PD Progression Using CGI-S Scale
Efficacy of Hydroxychloroquine (HCQ) in Delaying Clinical PD Progression Using PGI-S Scale
Efficacy of Hydroxychloroquine (HCQ) in Delaying Clinical PD Progression Using PGI-C Scale
Change in Quality of Life (QoL) as assessed by the PDQ-8
Show 2 moreShow less
Efficacy of Hydroxychloroquine (HCQ) Using Change in Modified Hoehn and Yahr Scale
Efficacy of Hydroxychloroquine (HCQ) in Slowing Clinical Disease Progression as Assessed by the MDS-UPDRS

Arms and interventions

Hydroxychloroquine Treatment for Early Parkinson's Disease (HCQ-PD)Experimental

This is an open-label study where 40 participants with early-treated Parkinson's Disease will be receive 200mg of Hydroxychloroquine, orally, twice daily for 48 weeks.

Drugs: Hydroxychloroquine (HCQ)

Sites

1 site in 1 country

  • The Ottawa HospitalOttawa, Ontario, Canada